Depression Drugs Market
Depression Drugs Market Analysis By Drug Type (Generic Depression Drugs, Branded Depression Drugs), By Drug Class (Serotonin-norepinephrine Reuptake Inhibitors), By Disease (Major Depressive Disorder, Generalized Anxiety Disorder), By Distribution Channel - Regional Forecast 2031
Analysis of Depression Drugs market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Depression Drugs Market Outlook
The global depression drugs market reached a valuation of around US$ 13 Bn in 2020, which amounts to close to 50% share of the psychotropic drugs market.
| Report Attributes | Details |
|---|---|
| Depression Drugs Market Size (2020) | US$ 13 Bn |
| Sales Forecast for Depression Drugs (2031) | US$ 20 Bn |
| Global Market Growth Rate (2021 to 2031) | 4% CAGR |
| Share of Top 5 Depression Drug Manufacturers | 40% |
Sales of depression drugs are slated to accelerate at a CAGR of 4% to top US$ 20 Bn by 2031. Demand for serotonin-norepinephrine reuptake inhibitors (SNRIs), which hold the highest market share, is set to increase at a CAGR of 2% across the assessment period of 2021 to 2031.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Consumption Analysis of Depression Drugs (2016 to 2020) Vs Market Outlook (2021 to 2031)
As per Fact.MR, a market research and competitive intelligence provider, the global market for depression drugs was valued at US$ 13 Bn in 2020.
According to the World Health Organization (WHO), depression is one of the primary causes of disability, affecting more than 350 Mn people worldwide. Major factors driving growth of the depression medications market are the rising prevalence of mental diseases such as social anxiety and depression and increasing demand for serotonin-norepinephrine reuptake inhibitors (SNRIs).
Discovery of innovative approaches for development of tricyclic antidepressants with minimum side effects and long-term results, together with rising acceptance of new treatments, is expected to propel market expansion over the coming years.
Government measures to make basic treatment for all mental health issues more accessible will help the market expansion. Furthermore, rising concern about the disease condition and essential therapeutic demands, increase in the number of people suffering from stress, and rising sales of CNS stimulants are driving the market growth.
Latest trends of depression drugs, the presence of top distributors of antidepressants, and growing sales of selective serotonin reuptake inhibitors (SSRIs) are driving the market growth.
All of these factors are expected to drive the market at 4% CAGR across 2021 to 2031.
How are Research & Development Activities Fueling Depression Drug Sales?
Traditional depression-managing medications and treatments have a low success rate, with just 40% of patients reportedly recovering. These concerns have driven academics, scientists, and medication makers to look for novel approaches to improve the efficacy of major depressive disorder treatments.
Over the last few years, advances in the neuroscience of depression have opened up new anxiety disorders and depression treatment options. Moreover, market players are actively focusing on the development of novel non-pharmacologic and pharmacologic therapies in the existing mental health drugs market.
Growing demand for tricyclic antidepressants, rising sales of selective serotonin reuptake inhibitors (SSRIs), and increasing use of antidepressants are driving the market growth.
Several international research projects are increasingly assisting in the creation of new pharmaceuticals, treatments, and cures. The overall growth of the depression medicines market is likely to be influenced by research and development initiatives.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Will Side Effects of Depression Drugs Create Reluctance among Patients?
Depression medications lose their efficacy after a few months or years since the brain becomes less responsive to such drugs. As a result, the normal brain functions begin to hamper.
Symptoms such as blurred vision, vivid dreams, insomnia, fatigue, dizziness, and loss of coordination are observed by the patients who discontinue the intake of antidepressants. These after-effects caused by depression medications are anticipated to limit the growth of the global depression medicines market.
Which is the Most Profitable Regional Market for Depression Drug Manufacturers?
North America is likely to be a major revenue-generating region. Revenue from the North American regional market is projected to expand 1.3X by 2031.
North America constitutes the largest share of the global antidepressant market, given the high concentration of established market players who are focusing on enhancing the efficiency of mental health drugs.
Rise in awareness pertaining to anxiety disorders and depression treatment created by mental healthcare organizations, growing online sales of CNS stimulants, and increasing adoption of depression medications are expected to drive growth of the market in this region.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Country-wise Analysis
What is the Demand Outlook for Depression Drugs in the U.S.?
The U.S. market for depression drugs is expected to increase 1.5X by 2031. In the United States, the geriatric population is growing, which is likely to open up additional chances for market players.
According to the Anxiety and Depression Association of America's Facts and Statistics., anxiety disorder is among the most prevalent mental illnesses in the United States, affecting around 40 Mn American adults each year, or 18.1% of the total population of the country.
In addition, more than 16.1 million persons in the United States suffer from severe depressive illness each year, with women having a higher prevalence than males.
As a result, growing frequency of illnesses, the rising rate of antidepressant consumption, and the presence of depression drug manufacturers are projected to fuel the market growth in the U.S. over the forecast period.
How Lucrative is the Market for Depression Drugs in China?
Increasing R&D investments by government and market participants, development of novel medications for anxiety and depression-related diseases, and increasing demand for branded antidepressants are expected to drive the market expansion in China.
The market in China is expanding due to rising sales of atypical antipsychotics among adults, growing demand for serotonin antagonist and reuptake inhibitors, and increasing frequency of depressive syndromes among the younger population.
Category-wise Insights
Why are Serotonin-norepinephrine Reuptake Inhibitors (SNRIs) in Such High Demand?
Serotonin-norepinephrine reuptake inhibitors (SNRIs) is expected to contribute the largest share in the market. Sales of SNRIs are expected to increase 2X over the forecast period.
Low levels of serotonin and norepinephrine are linked to depression. These are neurotransmitters, or chemical messengers, which have been shown to have an impact on mood. Serotonin-norepinephrine reuptake inhibitors are a category of antidepressants that work by inhibiting the reuptake of serotonin and norepinephrine by nerves.
While these medications are often thought of as a group of interconnected antidepressants based on reuptake inhibition, their chemical structures and pharmacological effects range significantly.
Patients with anxiety and depressive disorders are treated with SNRIs as a second-line medication. Growing applications in the treatment of abnormal psychological alterations with improved efficacy will boost the demand for serotonin-norepinephrine reuptake inhibitors. These medications have also been shown to be useful in the treatment of long-term nerve discomfort in anxiety disorders.
How is Rising Incidence of Major Depressive Disorders among Populations Driving Market Growth?
Major depressive disorder has been envisaged to account for the most substantial share in the depression drugs market based on disease type. Major depressive disorder is the leading cause of market growth since the majority of people are diagnosed with this disorder as a result of increased stress levels.
The biological, psychological, and social sources of sadness are all possible causes of major depressive disorder. Family history, substantial life changes, particular medications, chronic health conditions, and substance abuse are all key risk factors.
According to the Substance Abuse and Mental Health Services Association, adolescents aged 12 to 17 years old had the greatest prevalence of major depressive disorder (MDD), followed by adults aged 18 to 25 years old.
Growing prevalence of major depressive disorder as well as rising awareness regarding depression therapy and management among the younger population is driving the growth of the antidepressant drugs market.
Competitive Landscape
Top manufacturers in the depression drugs market are adopting sustainable growth strategies to diversify their product portfolio, sustain their position in the global market, intensify their customer base, and garner share in the global depression medicines market.
- In June 2021, Nippon Chemiphar Co., Ltd and Sumitomo Dainippon Pharma Co., Ltd announced a joint R&D agreement as well as an agreement for the clinical study of the novel antidepressant candidate NC-2800.
Depression Drugs Industry Report Scope
| Attribute | Details |
|---|---|
| Forecast Period | 2021 to 2031 |
| Historical Data Available for | 2016 to 2020 |
| Market Analysis | Value in US$ Mn |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East Africa |
| Key Countries Covered | U.S., Canada, Mexico, Brazil, Mexico, Argentina, Germany, Italy, France, U.K, Nordic, Spain, Japan, China, India, Malaysia, Thailand, Australia, GCC Countries, South Africa, Turkey |
| Key Market Segments Covered | Drug Type, Drug Class, Disease Type, Distribution Channel, Region |
| Key Companies Profiled | Johnson and Johnson; Sebela Pharmaceutical Inc.; Takeda Pharmaceutical Company Ltd.; GlaxoSmithKline; Novartis AG; Allergan USA Inc.; AstraZeneca; Pfizer Inc.; Eli Lilly and Company; Otsuka Pharmaceutical Co. Ltd.; Alkermes Plc; Bristol Myers Squibb Co.; H. Lundbeck; Teva Pharmaceutical Industries Ltd. |
| Pricing | Available upon Request |
Key Segments in Depression Drugs Industry Research
-
By Drug Type:
- Generic
- Branded
-
By Drug Class:
- Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Atypical Antipsychotics
- Central Nervous System (CNS) Stimulants
- Tricyclic Antidepressants
- Monoamine Oxidase Inhibitors
-
By Disease Type:
- Major Depressive Disorder
- Obsessive-Compulsive Disorder
- Generalized Anxiety Disorder
- Panic Disorder
- Schizophrenia
- Bipolar 1 Disorder
-
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Table of Content
- 1. Preface
- 2. Assumptions and Acronyms Used
- 3. Research Approach & Methodology
- 4. Executive Summary: Global Market
- 5. Market Overview
- 6. Market Dynamics
- 7. Global Market, by Drug Class
- 7.1. Atypical antipsychotics
- 7.2. Serotonin-norepinephrine reuptake inhibitors
- 7.3. Selective serotonin reuptake inhibitors
- 7.4. CNS stimulants
- 7.5. Others (Benzodiazepines and miscellaneous antidepressants)
- 8. Global Market, by Disease Type
- 8.1. Major Depressive Disorder
- 8.2. Schizophrenia and bipolar I disorder (manic depression)
- 8.3. SSRI induced
- 8.4. Others (attention deficit hyperactivity disorder and anxiety disorders)
- 9. Global Market, by Distribution Channel
- 9.1. Hospital pharmacies
- 9.2. Retail pharmacies
- 9.3. Online pharmacies
- 10. Global Market, by Region
- 10.1. North America
- 10.2. Europe
- 10.3. Asia Pacific
- 10.4. Latin America
- 10.5. Middle East & Africa
- 11. North America Market Analysis
- 12. Europe Market Analysis
- 13. Asia Pacific Market Analysis
- 14. Latin America Market Analysis
- 15. Middle East & Africa Market Analysis
- 16. Competition Landscape
- 16.1. Otsuka Pharmaceutical Co., Ltd.
- 16.2. Eli Lilly and Company
- 16.3. Pfizer, Inc.
- 16.4. AstraZeneca plc.
- 16.5. Novartis AG
- 16.6. GlaxoSmithKline plc
- 16.7. Takeda Pharmaceutical Company Ltd
- 16.8. Sebela Pharmaceutical Inc.
- 16.9. Allergan USA, Inc.
- 16.10. Johnson & Johnson
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Opportunity Map, by Drug Class, 2021
Table 02: Opportunity Map, by Disease Type, 2021
Table 03: Opportunity Map, by Distribution Channel, 2021
Table 04: Global Market Size (US$ Mn) Forecast, by Drug Class, 2021 to 2031
Table 05: Global Market Size (US$ Mn) Forecast, by Disease Type, 2020 to 2031
Table 06: Global Market Size (US$ Mn) Forecast, by Distribution Channel, 2020 to 2031
Table 07: Global Market (US$ Mn) Forecast, by Region, 2020 to 2031
Table 08: North America Market Size (US$ Mn) Forecast, by Drug Class, 2020 to 2031
Table 09: North America Market Size (US$ Mn) Forecast, by Disease Type, 2020 to 2031
Table 10: North America Market Size (US$ Mn) Forecast, by Distribution Channel, 2020 to 2031
Table 11: North America Market Size (US$ Mn) Forecast, by Country, 2020 to 2031
Table 12: U.S. Market Size (US$ Mn) Forecast, by Drug Class, 2020 to 2031
Table 13: U.S. Market Size (US$ Mn) Forecast, by Disease Type, 2020 to 2031
Table 14: U.S. Market Size (US$ Mn) Forecast, by Distribution Channel, 2020 to 2031
Table 15: Canada Market Size (US$ Mn) Forecast, by Drug Class, 2020 to 2031
Table 16: Canada Market Size (US$ Mn) Forecast, by Disease Type, 2020 to 2031
Table 17: Canada Market Size (US$ Mn) Forecast, by Distribution Channel, 2020 to 2031
Table 18: Europe Market Size (US$ Mn) Forecast, by Drug Class, 2020 to 2031
Table 19: Europe Market Size (US$ Mn) Forecast, by Disease Type, 2020 to 2031
Table 20: Europe Market Size (US$ Mn) Forecast, by Distribution Channel, 2020 to 2031
Table 21: Europe Market Size (US$ Mn) Forecast, by Country, 2020 to 2031
Table 22: Germany Market Size (US$ Mn) Forecast, by Drug Class, 2020 to 2031
Table 23: Germany Market Size (US$ Mn) Forecast, by Disease Type, 2020 to 2031
Table 24: Germany Market Size (US$ Mn) Forecast, by Distribution Channel, 2020 to 2031
Table 25: France Market Size (US$ Mn) Forecast, by Drug Class, 2020 to 2031
Table 26: France Market Size (US$ Mn) Forecast, by Disease Type, 2020 to 2031
Table 27: France Market Size (US$ Mn) Forecast, by Distribution Channel, 2020 to 2031
Table 28: Italy Market Size (US$ Mn) Forecast, by Drug Class, 2020 to 2031
Table 29: Italy Market Size (US$ Mn) Forecast, by Disease Type, 2020 to 2031
Table 30: Italy Market Size (US$ Mn) Forecast, by Distribution Channel, 2020 to 2031
Table 31: Spain Market Size (US$ Mn) Forecast, by Drug Class, 2020 to 2031
Table 32: Spain Market Size (US$ Mn) Forecast, by Disease Type, 2020 to 2031
Table 33: Spain Market Size (US$ Mn) Forecast, by Distribution Channel, 2020 to 2031
Table 34: U.K. Market Size (US$ Mn) Forecast, by Drug Class, 2020 to 2031
Table 35: U.K. Market Size (US$ Mn) Forecast, by Disease Type, 2020 to 2031
Table 36: U.K. Market Size (US$ Mn) Forecast, by Distribution Channel, 2020 to 2031
Table 37: Rest of Europe Market Size (US$ Mn) Forecast, by Drug Class, 2020 to 2031
Table 38: Rest of Europe Market Size (US$ Mn) Forecast, by Disease Type, 2020 to 2031
Table 39: Rest of Europe Market Size (US$ Mn) Forecast, by Distribution Channel, 2020 to 2031
Table 40: Asia Pacific Market Size (US$ Mn) Forecast, by Drug Class, 2020 to 2031
Table 41: Asia Pacific Market Size (US$ Mn) Forecast, by Disease Type, 2020 to 2031
Table 42: Asia Pacific Market Size (US$ Mn) Forecast, by Distribution Channel, 2020 to 2031
Table 43: Asia Pacific Market Size (US$ Mn) Forecast, by Country, 2020 to 2031
Table 44: China Market Size (US$ Mn) Forecast, by Drug Class, 2020 to 2031
Table 45: China Market Size (US$ Mn) Forecast, by Disease Type, 2020 to 2031
Table 46: China Market Size (US$ Mn) Forecast, by Distribution Channel, 2020 to 2031
Table 47: Japan Market Size (US$ Mn) Forecast, by Drug Class, 2020 to 2031
Table 48: Japan Market Size (US$ Mn) Forecast, by Disease Type, 2020 to 2031
Table 49: Japan Market Size (US$ Mn) Forecast, by Distribution Channel, 2020 to 2031
Table 50: India Market Size (US$ Mn) Forecast, by Drug Class, 2020 to 2031
Table 51: India Market Size (US$ Mn) Forecast, by Disease Type, 2020 to 2031
Table 52: India Market Size (US$ Mn) Forecast, by Distribution Channel, 2020 to 2031
Table 53: Australia & New Zealand Market Size (US$ Mn) Forecast, by Drug Class, 2020 to 2031
Table 54: Australia & New Zealand Market Size (US$ Mn) Forecast, by Disease Type, 2020 to 2031
Table 55: Australia & New Zealand Market Size (US$ Mn) Forecast, by Distribution Channel, 2020 to 2031
Table 56: Rest of Asia Pacific Market Size (US$ Mn) Forecast, by Drug Class, 2020 to 2031
Table 57: Rest of Asia Pacific Market Size (US$ Mn) Forecast, by Disease Type, 2020 to 2031
Table 58: Rest of Asia Pacific Market Size (US$ Mn) Forecast, by Distribution Channel, 2020 to 2031
Table 59: Latin America Market Size (US$ Mn) Forecast, by Drug Class, 2020 to 2031
Table 60: Latin America Market Size (US$ Mn) Forecast, by Disease Type, 2020 to 2031
Table 61: Latin America Market Size (US$ Mn) Forecast, by Distribution Channel, 2020 to 2031
Table 62: Latin America Market Size (US$ Mn) Forecast, by Country, 2020 to 2031
Table 63: Brazil Market Size (US$ Mn) Forecast, by Drug Class, 2020 to 2031
Table 64: Brazil Market Size (US$ Mn) Forecast, by Disease Type, 2020 to 2031
Table 65: Brazil Market Size (US$ Mn) Forecast, by Distribution Channel, 2020 to 2031
Table 66: Mexico Market Size (US$ Mn) Forecast, by Drug Class, 2020 to 2031
Table 67: Mexico Market Size (US$ Mn) Forecast, by Disease Type, 2020 to 2031
Table 68: Mexico Market Size (US$ Mn) Forecast, by Distribution Channel, 2020 to 2031
Table 69: Rest of Latin America Market Size (US$ Mn) Forecast, by Drug Class, 2020 to 2031
Table 70: Rest of Latin America Market Size (US$ Mn) Forecast, by Disease Type, 2020 to 2031
Table 71: Rest of Latin America Market Size (US$ Mn) Forecast, by Distribution Channel, 2020 to 2031
Table 72: Middle East & Africa Market Size (US$ Mn) Forecast, by Drug Class, 2020 to 2031
Table 73: Middle East & Africa Market Size (US$ Mn) Forecast, by Disease Type, 2020 to 2031
Table 74: Middle East & Africa Market Size (US$ Mn) Forecast, by Distribution Channel, 2020 to 2031
Table 75: Middle East & Africa Market Size (US$ Mn) Forecast, by Country, 2020 to 2031
Table 76: GCC Market Size (US$ Mn) Forecast, by Drug Class, 2020 to 2031
Table 77: GCC Market Size (US$ Mn) Forecast, by Disease Type, 2020 to 2031
Table 78: GCC Market Size (US$ Mn) Forecast, by Distribution Channel, 2020 to 2031
Table 79: South Africa Market Size (US$ Mn) Forecast, by Drug Class, 2020 to 2031
Table 80: South Africa Market Size (US$ Mn) Forecast, by Disease Type, 2020 to 2031
Table 81: South Africa Market Size (US$ Mn) Forecast, by Distribution Channel, 2020 to 2031
Table 82: Israel Market Size (US$ Mn) Forecast, by Drug Class, 2020 to 2031
Table 83: Israel Market Size (US$ Mn) Forecast, by Disease Type, 2020 to 2031
Table 84: Israel Market Size (US$ Mn) Forecast, by Distribution Channel, 2020 to 2031
Table 85: Rest of Middle East & Africa Market Size (US$ Mn) Forecast, by Drug Class, 2020 to 2031
Table 86: Rest of Middle East & Africa Market Size (US$ Mn) Forecast, by Disease Type, 2020 to 2031
Table 87: Rest of Middle East & Africa Market Size (US$ Mn) Forecast, by Distribution Channel, 2020 to 2031
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Size (US$ Mn), by Drug Class, 2021 (A)
Figure 02: Global Market Revenue (%), 2021 (A)
Figure 03: Global Market Size (US$ Mn) Forecast, 2020 to 2031
Figure 04: Market Value Share, by Drug Class (2021)
Figure 05: Market Value Share, by Disease Type (2021)
Figure 06: Market Value Share, by Distribution Channel (2021)
Figure 07: Market Value Share, by Region (2021)
Figure 08: Global Market Value Share, by Valence, 2021 and 2031
Figure 09: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Atypical antipsychotics, 2021 to 2031
Figure 10: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by SNRI, 2021 to 2031
Figure 11: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by SSRI, 2021 to 2031
Figure 12: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by CNS stimulants, 2021 to 2031
Figure 13: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2021 to 2031
Figure 14: Global Market Value Share, by Disease Type, 2021 and 2031
Figure 15: Global Market Revenue (US$ Mn), by MDD, 2021 to 2025
Figure 16: Global Market Revenue (US$ Mn), by Schizophrenia and bipolar I disorder, 2021 to 2025
Figure 17: Global Market Revenue (US$ Mn), by SSRI induced, 2020 to 2031
Figure 18: Global Market Revenue (US$ Mn), by Others, 2020 to 2031
Figure 19: Global Market Value Share, by Distribution Channel, 2021 and 2031
Figure 20: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital pharmacies, 2020 to 2031
Figure 21: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail pharmacies, 2020 to 2031
Figure 22: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online pharmacies, 2020 to 2031
Figure 23: Global Market Analysis, by Region, 2021 and 2031
Figure 24: North America Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020 to 2031
Figure 25: North America Market Value Share, by Drug Class, 2021 and 2031
Figure 26: North America Market Value Share, by Disease Type, 2021 and 2031
Figure 27: North America Market Value Share, by Distribution Channel, 2021 and 2031
Figure 28: North America Market Value Share, by Country, 2021 and 2031
Figure 29: Europe Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020 to 2031
Figure 30: Europe Market Value Share, by Drug Class, 2021 and 2031
Figure 31: Europe Market Value Share, by Disease Type, 2021 and 2031
Figure 32: Europe Market Value Share, by Distribution Channel, 2021 and 2031
Figure 33: Europe Market Value Share, by Country/Sub Region, 2021 and 2031
Figure 34: Asia Pacific Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020 to 2031
Figure 35: Asia Pacific Market Value Share, by Drug Class, 2021 and 2031
Figure 36: Asia Pacific Market Value Share, by Disease Type, 2021 and 2031
Figure 37: Asia Pacific Market Value Share, by Distribution Channel, 2021 and 2031
Figure 38: Asia Pacific Market Value Share, by Country/Sub Region, 2021 and 2031
Figure 39: Latin America Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020 to 2031
Figure 40: Latin America Market Value Share, by Drug Class, 2021 and 2031
Figure 41: Latin America Market Value Share, by Disease Type, 2021 and 2031
Figure 42: Latin America Market Value Share, by Distribution Channel, 2021 and 2031
Figure 43: Latin America Market Value Share, by Country, 2021 and 2031
Figure 44: Middle East & Africa Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020 to 2031
Figure 45: Middle East & Africa Market Value Share, by Drug Class, 2021 and 2031
Figure 46: Middle East & Africa Market Value Share, by Disease Type, 2021 and 2031
Figure 47: Middle East & Africa Market Value Share, by Distribution Channel, 2021 and 2031
Figure 48: Middle East & Africa Market Value Share, by Country/Sub Region, 2021 and 2031
Figure 49: Sales Analysis, 2016 to 2020
Figure 50: Market Share, by Company, 2021
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the current global market worth for depression drugs?
The global depression drugs market is currently worth more than US$ 13 Bn.
What was the last 5 year’s market CAGR for the sales of depression drugs?
From 2016 to 2020, the market for depression drugs increased at around 1% CAGR.
What are key trends likely to influence sales of depression drugs?
Rise in prevalence of depression and growing geriatric population are major factors driving growth of the market.
Who are the prominent manufacturers of depression drugs?
Key depression drug suppliers are Johnson and Johnson, Sebela Pharmaceutical Inc., Takeda Pharmaceutical Company Ltd., GlaxoSmithKline, and Novartis AG.
Which region is most attractive for depression drug vendors?
With 40% share, North America will largely contribute to the growth of depression drugs revenue.
How lucrative is the opportunity for market expansion in Germany?
Sales of antidepressants in Germany are expected to rise at a CAGR of 1% over the forecast period of 2021 to 2031.
Which drug class has the largest share in the market for depression drugs?
Serotonin-norepinephrine reuptake inhibitors (SNRIs) account for a share of 60% in the market.
Which are the top 5 countries driving demand for depression drugs?
The U.S., China, U.K, Germany, and France are expected to drive most of the demand for depression drugs.
Which distribution channel is expected to hold the highest share for the sales for depression drugs?
Online pharmacies are expected to hold more than 40% market share for depression drugs.
What is the predicted expansion rate for the market over the next ten years?
The global market is expected to expand at a CAGR of 4% over the forecast period of 2021 to 2031.
Depression Drugs Market